silver benzylsulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: silver benzylsulfonate
• 英文别名: silver;phenylmethanesulfonate
• 化学式: Ag*C₇H₇O₃S
• 分子量: 279.065
• InChiKey: HYEUZIAXGDWFMP-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.73
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  silver benzylsulfonate 、 二乙基三甲基硅基亚磷酸盐 在 溴 作用下， 生成 O,O'-diethylphosphoric benzylsulfonic anhydride
  参考文献：
  名称：

  通过溴化磷和碘化磷与磺酸的银盐的反应合成磷和磺酸酐混合酸酐的新方法：合成P-手性酸酐的途径

  摘要：

  磷酸溴化物和碘化物与磺酸的银盐的反应导致以优异的产率形成混合的磷和磺酸酐3。该方法允许首先合成含有P-手性中心的混合酸酐。随后将它们分离为纯的非对映异构体。

  DOI：

  10.1016/s0040-4039(00)78575-3

文献信息

• Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
  申请人：Banholzer Rolf

  公开号：US20050096341A1

  公开（公告）日：2005-05-05

  The invention relates to new tiotropium salts, processes for preparing them, pharmaceutical formulations containing them and their use for preparing a medicament for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

  本发明涉及新的噻托溴铵盐、其制备方法、含有它们的药物制剂以及用于制备治疗呼吸道疾病的药物，特别是用于治疗慢性阻塞性肺疾病（COPD）和哮喘。
• Preparation of cepham derivatives
  申请人：ELI LILLY AND COMPANY

  公开号：EP0082656A2

  公开（公告）日：1983-06-29

  There is described the production of a 7-epi-3- exomethylenecepham, useful in the synthesis of antibiotic compounds, by a process which comprises reducing a sulfoxide of formula (II): or acetoxymethyl derivative of formula (III): when n is 0 or 1 and R is hydrogen or an acyl group and R1 is hydrogen, a carboxy-protecting group, or a cation.

  描述了一种用于合成抗生素化合物的 7-表-3-外亚甲基樟脑的生产工艺，该工艺包括还原式（II）的亚砜：或式（III）的乙酰氧甲基衍生物：当 n 为 0 或 1，R 为氢或酰基，R1 为氢、羧基保护基团或阳离子时。
• TWO-QUATERNARY AMMONIUM COMPOUND AND PREPARATION METHOD AND USE THEREOF
  申请人：West China Hospital, Sichuan University

  公开号：EP3828168A1

  公开（公告）日：2021-06-02

  Disclosed are a two-quaternary ammonium compound and a preparation method and a use thereof. Specifically, a two-quaternary ammonium compound depicted by formula (I) is provided: wherein L1 is a C1 to C8alkylene group; L2 is a C1 to C8 alkylene group; Z1 is nitro group or a halogen or methoxy group; Z2 is nitro group or a halogen or methoxy group; Z3 is nitro group or a halogen or methoxy group; R = H or a C1 to C6 alkyl group; a , b, and c are independently an integer from 0-5; and M is a pharmaceutically acceptable anion, such as a bromine ion, chlorine ion, sulfonate radical, etc. A stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate or eutectic of the compound depicted by formula (I) forms a composition with a pharmaceutically acceptable carrier, or forms a compounded prescription with other active components, and said composition or compounded prescription may be used in the preparation of a muscle relaxant.

  本发明公开了一种双季铵化合物及其制备方法和用途。具体而言，提供了一种由式（I）描述的双季铵化合物：其中 L1 是 C1 至 C8 烯基；L2 是 C1 至 C8 烯基；Z1 是硝基或卤素或甲氧基；Z2 是硝基或卤素或甲氧基；Z3 是硝基或卤素或甲氧基；R = H 或 C1 至 C6 烷基；a、b 和 c 独立地为 0-5 的整数；M 是药学上可接受的阴离子，如溴离子、氯离子、磺酸基等。式（I）所示化合物的立体异构体或立体异构体混合物，或其药学上可接受的盐或溶解物或共晶与药学上可接受的载体形成组合物，或与其他活性成分形成复方，所述组合物或复方可用于制备肌肉松弛剂。
• Class of bisquaternary ammonium compound as well as the preparative method and the use thereof
  申请人：WEST CHINA HOSPITAL, SICHUAN UNIVERSITY

  公开号：US11161828B2

  公开（公告）日：2021-11-02

  A two-quaternary ammonium compound has a structural formula of formula (I). L1 is a C1 to C8 alkylene group; L2 is a C1 to C8 alkylene group; Z1 is nitro group or a halogen or methoxy group; Z2 is nitro group or a halogen or methoxy group; Z3 is nitro group or a halogen or methoxy group; R═H or a C1 to C6 alkyl group; a, b, and c are independently an integer from 0-5; and M is a pharmaceutically acceptable anion, such as a bromine ion, chlorine ion, sulfonate radical, etc. A stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate or eutectic of the compound of formula (I) forms a composition with a pharmaceutically acceptable carrier, or forms a compounded prescription with other active components, and the composition or compounded prescription may be used in the preparation of a muscle relaxant.

  一种双季铵化合物的结构式为式(I)。L1 是 C1 至 C8 亚烷基；L2 是 C1 至 C8 亚烷基；Z1 是硝基或卤素或甲氧基；Z2 是硝基或卤素或甲氧基；Z3 是硝基或卤素或甲氧基；R═H 或 C1 至 C6 烷基；a、b 和 c 独立地为 0-5 的整数；M 是药学上可接受的阴离子，如溴离子、氯离子、磺酸基等。式（I）化合物的立体异构体或立体异构体混合物，或药学上可接受的盐或溶解物或共晶与药学上可接受的载体形成组合物，或与其他活性成分形成复方制剂，该组合物或复方制剂可用于制备肌肉松弛剂。
• Water-absorbing polymer particles inhibiting the breakdown of body fluids, composites comprising the same and use thereof
  申请人：Harren Jorg

  公开号：US20050171235A1

  公开（公告）日：2005-08-04

  Water-absorbing, antimicrobial polymer particles comprising from about 1 to about 500 ppm, based on the particles, of a silver ion based on a silver salt, wherein the silver salt has a solubility product of at least about 1×10 −8 (mol/l) m+n ; at least about 10 wt. %, based on the polymer particle, of a water-absorbing polymer based on: (α1) from about 50 to about 99.99 wt. % polymerized, ethylenically unsaturated, acid groups-containing monomers or salts thereof, (α2) 0 to about 40 wt. % polymerized, mono-ethylenically unsaturated monomers polymerizable with α1, (α3) from about 0.01 to about 5 wt. %, preferably from about 0.1 to about 3 wt. % of one or more crosslinkers, (α4) 0 to about 30 wt. % of a water soluble polymer and (α5) 0 to about 20 wt. % of auxiliaries, the concentration of the silver ion based on a silver salt in at most about 90 vol. % of the particles is less than about 0.01 ppm.

  吸水性抗菌聚合物颗粒，以颗粒为基础，包含约 1 至约 500 ppm 的银离子（基于银盐），其中银盐的溶度积至少为约 1×10 -8 (摩尔/升） m+n (α1)约 50 至约 99.99 重量％的聚合的含酸基团的乙烯基不饱和单体或其盐，(α2)0 至约 40 重量％的可与 α1聚合的单乙烯基不饱和单体，(α3)约 0.01至约5重量％，最好是约0.1至约3重量％的一种或多种交联剂，(α4)0至约30重量％的水溶性聚合物和(α5)0至约20重量％的助剂，在至多约90体积％的颗粒中基于银盐的银离子浓度小于约0.01ppm。